Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins and their use as blood anticoagulants and for treating sepsis.

Abstract: Disclosed are fluidic devices and methods for preparing fluidic devices. More particularly, disclosed are fluidic devices having fiber scaffolds and methods for their preparation. Also disclosed are methods for culturing cells using the fluidic devices having fiber scaffolds.

Abstract: Compositions and methods for delivering enzymes in enzyme hydrogel formulations are disclosed. More particularly, the present disclosure relates to injectable enzyme hydrogel formulations and delivery of injectable enzyme hydrogel formulations. Also disclosed are methods for GALNS enzyme replacement therapy and lysosomal enzyme replacement therapy.

Abstract: In one aspect, the present disclosure provides a compound of the formula: In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

Abstract: Methods of determining an immune status of a subject are provided. Specifically, methods for determining whether a subject has been exposed to an immunogenic antigen are provided as well as methods for determining efficacy of a vaccine are described.

Abstract: The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.

Abstract: Described are glutathione adducts of fatty aldehydes (FALD-GSH) and methods useful in the detection of FALD-GSH in the identification of pathologies associated with leukocyte-mediated disease conditions, including eosinophil and neutrophil activation. Thus, the present disclosure provides methods of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising (a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample; (b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and (c) diagnosing the subject as having or being at risk of developing LMD if the level of FALD-GSH in the sample is higher than the control or standard.

Abstract: The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins, vectors, host cells and methods for preparing the thrombin-thrombomodulin fusion proteins. The present disclosure further relates to methods for measuring protein C in plasma and kits for measuring protein C in plasma.

Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

Abstract: Disclosed are methods of diagnosing and treating endometriosis, and in particular, endometriosis-associated infertility.

Abstract: The disclosure provides methods and compositions for inhibiting pain by administering a GPR160 antagonist to a subject in need thereof. Also provided are methods of using GPR160 antagonists in combination with other pain therapies.

Abstract: The present disclosure provides for peptides derived from membrane-anchored ubiquitin-fold proteins (MUB), particularly those containing a Lap-Bar-Lopp motif, for use in inhibiting ubiquitinylation.

Abstract: The present invention generally relates to various polycyclic aromatic selenoxide compounds, methods for preparing these compounds, and methods of us these and other compounds to generate ground state atomic oxygen.

Abstract: The present disclosure relates to vaccine formulations and their use in treating and preventing Chagas Disease.

Abstract: Disclosed are methods and compositions for reduced immunogenic proteins used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are genetically engineered variants of N-acetylgalactosamine-6-sulfatase (GALNS), which are less immunogenetic then wild-type GALNS, but maintain enzymatic activity, and may be used to treat Mucopolysaccharidosis IVA (Morquio A disease, MPS IVA).

Abstract: Disclosed herein are methods for transferring carbon nanotubes on a hydrogel scaffold. Carbon nanotubes are formed on a substrate and directly transferred onto a hydrogel surface. Carbon nanotubes transferred according to the present disclosure can be used in tissue engineering applications and electrode coating applications.

Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

Abstract: The present disclosure provides methods of treating a patient comprising administering a p38 inhibitor for the treatment of FSHD. In some embodiments, the present methods comprise using one or more p38 inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Abstract: The present invention generally concerns a nano-enhanced explosive that is integrated at many points across an explosive train. More specifically, a nano-enhanced explosive is formed when a nanocomposite we call nMx is combined with a secondary high explosive. nMx is made of Li3AlH6 nanoparticles, elemental Al nanoparticles, an amount of Ti metal, and a nanoscale organic layer having unique burning profiles that lend energy to the explosive process including increased shockwave propagation through a chemical explosive and increased temperatures and gaseous pressure build up and release in and about the same. Our nano-enhanced explosive can be integrated at various points across an explosive train, e.g. use within a detonation cord (fuse), or as a detonation charge (initiator), or as the main charge, where the use of the nano-enhanced explosive can be characterized by the energy lent to projectiles from munitions, bubbles formed by underwater explosive trains, or blast profiles.